Prostatic Hyperplasia: Clinical Trials

48 trials for Prostatic Hyperplasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

48 completed. 48 Phase 1, 6 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 148Completed 48
Phase 26Completed 6

Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia

Trials (filtered) newest first · largest first

All 48 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
CKD-846, D091 - Benign Prostate Hypertrophy(BPH)
Phase 1CompletedChong Kun Dang Pharmaceutical342026-02-232026-07-21
A Clinical Trial to Evaluate the Safety and the Pharmacokinetics of AD-116 Compared to AD-1161 in Healthy Adult Male Volunteers
AD-116, AD-1161 - Benign Prostatic Hyperplasia
Phase 1CompletedAddpharma Inc.442026-01-222026-07-28
BOTOX Injection Technique for LUTS Due to BPH
Botulinum Toxin Type A (BoNT-A) - Benign Prostatic Hyperplasia
Phase 1CompletedBenha University602025-10-012026-06-12
A Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
CKD-846, D091 - Benign Prostate Hypertrophy(BPH)
Phase 1CompletedChong Kun Dang Pharmaceutical312023-11-132026-01-14
A 3 Months Duration Interventional Study Comparing Hemodynamic Parameters Between Bolus and Fractionated Group.
0.5% Heavy Bupivacaine - Prostatic Hyperplasia, Benign
Phase 1CompletedNational Academy of Medical Sciences, Nepal722022-10-012024-10-08
A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
BR9006-1, BR9006-2 - Benign Prostatic Hyperplasia (BPH), Overactive Bladder
Phase 1CompletedBoryung Pharmaceutical Co., Ltd362020-07-202020-10-28
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers
Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab. - Benign Prostatic Hyperplasia
Phase 1CompletedChong Kun Dang Pharmaceutical302019-03-112020-01-30
Study to Evaluate the Bioequivalence of Astellas Phama Korea Inc. "Harnal-D" in Healthy Volunteers After Meal
Harnal-D Tab., Chong Kun Dang Tamsulosin HCl Tab. - Benign Prostatic Hyperplasia
Phase 1CompletedChong Kun Dang Pharmaceutical302019-03-112020-01-30
The Effect of Traditional Chinese Medicine on Benign Prostatic Hyperplasia
VGH-BPH1, Placebo (Corn starch pill manufactured to mimic VGH-BPH1) - Benign Prostatic Hyperplasia
Phase 1 / Phase 2CompletedTaipei Veterans General Hospital, Taiwan232019-03-062020-04-13
Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil
Dutasteride 0.5 mg, Tadalafil 5 mg, YY-201 - Benign Prostatic Hyperplasia
Phase 1CompletedYuyu Pharma, Inc.362017-03-272017-11-24
A Phase 1 Trial for Evaluation of the Safety, Pharmacokinetics, and [18F] Radiation Dosimetry of CTT1057
CTT1057, Prostatectomy - Prostate Cancer
Phase 1CompletedCancer Targeted Technology202016-09-012017-11-06
A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects
Tadalafil, Dutasteride - Benign Prostate Hyperplasia
Phase 1CompletedYuyu Pharma, Inc.282016-05-012017-04-04
A Clinical Trial to Evaluate the Effects of Food on the Bioavailability of CKD-397 in Healthy Male Subjects
CKD-397 - Benign Prostatic Hypertrophy (BPH)
Phase 1CompletedChong Kun Dang Pharmaceutical162015-12-012017-08-09
Study to Compare the Safety and Pharmacokinetics of CKD-397
CKD-397, TD+TM - Benign Prostatic Hyperplasia
Phase 1CompletedChong Kun Dang Pharmaceutical362015-11-012016-01-12
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers
HCP1303, HGP1201, HIP1402 - Erectile Dysfunction, Prostatic Hyperplasia
Phase 1CompletedHanmi Pharmaceutical Company Limited362015-10-012016-03-22
Bioequivalence Study of Dutasteride Capsules in Healthy Japanese Male Subjects
Dutasteride-Test product, Dutasteride-Reference product - Prostatic Hyperplasia
Phase 1CompletedGlaxoSmithKline362015-09-092018-06-19
The PK Study of the JLP-1207 and Solifenacin/Tamsulosin in Healthy Male Volunteers.
JLP-1207, Solifenacin 5mg+Tamsulosin 0.2mg - LUTS(Lower Urinary Tract Symptoms), Benign Prostatic Hyperplasia
Phase 1CompletedJeil Pharmaceutical Co., Ltd.542015-08-012016-06-24
Bioavailability Study of Fixed Dose Combination (FDC) Dutasteride and Tamsulosin Hydrochloride (HCl) Relative to One Dutasteride and One Tamsulosin HCl Tablet in Healthy Male Subjects
FDC capsule of dutasteride and tamsulosin, Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet - Prostatic Hyperplasia
Phase 1CompletedGlaxoSmithKline562015-07-302018-06-19
Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers
HCP1303, HGP1201, HIP1402 - Erectile Dysfunction, Prostatic Hyperplasia
Phase 1CompletedHanmi Pharmaceutical Company Limited302015-07-012016-03-18
Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers
JLP-1207(Fasted), JLP-1207(Fed) - LUTS, Benign Prostatic Hyperplasia
Phase 1CompletedJeil Pharmaceutical Co., Ltd.542015-07-012016-06-24

Showing 20 of 48. Sign in to see all of them.

Narrower conditions

Urinary Bladder, Overactive (6)  ·  Lower Urinary Tract Symptoms (5)  ·  Erectile Dysfunction (4)  ·  Fasting (1)  ·  Nocturia (1)  ·  Prostatic Diseases (1)  ·  Prostatic Neoplasms (1)  ·  Prostatitis (1)  ·  Urinary Bladder Neck Obstruction (1)  ·  Urinary Incontinence (1)

Broader conditions

Genital Diseases (48)  ·  Genital Diseases, Male (48)  ·  Male Urogenital Diseases (48)  ·  Urogenital Diseases (48)  ·  Prostatic Diseases (47)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Signs and Symptoms (10)  ·  Urological Manifestations (10)  ·  Female Urogenital Diseases (6)  ·  Female Urogenital Diseases and Pregnancy Complications (6)  ·  Urinary Bladder Diseases (6)  ·  Urologic Diseases (6)  ·  Lower Urinary Tract Symptoms (5)  ·  Mental Disorders (4)  ·  Sexual Dysfunction, Physiological (4)

Interventions

Tamsulosin (14)  ·  Dutasteride (12)  ·  Tadalafil (6)  ·  Solifenacin Succinate (3)  ·  Botulinum Toxins, Type A (2)  ·  1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (1)  ·  Embryo Implantation (1)  ·  Ethanol (1)  ·  Finasteride (1)  ·  PRX302 (1)  ·  Photochemotherapy (1)  ·  Prostatectomy (1)  ·  QLT0074 (1)  ·  Sildenafil Citrate (1)  ·  Sodium Chloride (1)

Sponsors

GlaxoSmithKline (13)  ·  Chong Kun Dang Pharmaceutical (6)  ·  Hanmi Pharmaceutical Company Limited (3)  ·  Jeil Pharmaceutical Co., Ltd. (3)  ·  Boehringer Ingelheim (2)  ·  Dongkook Pharmaceutical Co., Ltd. (2)  ·  Yuyu Pharma, Inc. (2)  ·  Addpharma Inc. (1)  ·  Allergan (1)  ·  American Medical Systems (1)  ·  Astellas Pharma Europe B.V. (1)  ·  Benha University (1)  ·  Boryung Pharmaceutical Co., Ltd (1)  ·  Cancer Targeted Technology (1)  ·  Eli Lilly and Company (1)

Countries

South Korea (15)  ·  United States (11)  ·  Australia (3)  ·  Brazil (2)  ·  Germany (2)  ·  Canada (1)  ·  China (1)  ·  Egypt (1)  ·  Japan (1)  ·  Nepal (1)  ·  Netherlands (1)  ·  Russia (1)  ·  Singapore (1)  ·  Taiwan (1)

Top investigators

Kyung-sang Yu, M.D., Ph.D. (2)  ·  Min Kyu Park, MD, PhD (2)  ·  Minsu Park, M.D., Ph.D. (2)  ·  Yu-Jung Cha (2)  ·  An-Hye Kim (1)  ·  Beatrice Langton-Webster, PhD (1)  ·  Georg Golor, PD Dr. med. (1)  ·  Hyeong-Seok Lim, M.D.,Ph.D. (1)  ·  Ji-Young Park, MD, PhD (1)  ·  Kyung-sang Yu, M.D.,Ph.D. (1)

Results publications

PMID 28800206